Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

dition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA; manufacturing development and capabilities; market prospects for its products, including with respect to AMRIX; sales, adjusted net income and basic adjusted income per common share guidance for 2007 and 2008; and other statements regarding matters that are not historical facts, including the Company's position and expected performance in 2007 and 2008, the final resolution or outcome of the ongoing investigations by the U.S. Attorney's Office and the Office of the Connecticut Attorney General and the final amount of any settlement and/or fines related thereto, and the relative strength of the foundation for the Company's ongoing compliance efforts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermo
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... May 13 -, EMERYVILLE, Calif., May 12 Neurobiological,Technologies, ... its fiscal third quarter and the nine months ended March ... 2008 were $3.7 million,compared to $4.9 million for the same ... $5.9 million for the third,quarter of 2008 compared to $7.7 ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a ... and stem cell research systems,today announced that Mr. ... a corporate presentation at the Rodman & Renshaw,Fifth ... held May,19-20, 2008, at the Le Meridien Beach ...
... Host Investor Conference Call on Monday, May 12, 2008 at 8:30am ... ... May 9 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company ... the treatment of life-threatening,diseases, including renal disease and cancer, today announced its ...
Cached Biology Technology:Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... against HIV increases the risk of developing clinical West Nile ... January 9th in The Journal of Experimental Medicine. , The ... that encodes a protein called CCR5, which was identified in ... Individuals with two copies of this mutation (CCR5delta32) are ...
... Gene variants determine which humans and which chimpanzees can ... influence nutritional choices and ultimately their health, as well ... a way to live safely in their environments by ... conducted more 65 years ago by a team of ...
... and Michael Emerman and colleagues at the Fred Hutchinson Cancer ... humans may be impaired in the function of a recently ... as HIV. , One of the key components of ... gene was discovered because the version of TRIM5 possessed by ...
Cached Biology News:Genetic mutation linked to West Nile virus infection 2Research updates 65-year-old genetic discovery 2Research updates 65-year-old genetic discovery 3
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... microcapillary flow cytometry accessible to anyone in ... appreciate the latest addition to Guavas on-demand ... surprising affordable, and very compact for higher ... features as absolute cell counts, 6 parameters ...
Biology Products: